Home › Castration-Resistant Prostatic Cancer › Minnesota
Castration-Resistant Prostatic Cancer clinical trials in Minnesota
4 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in Minnesota.
Cities in Minnesota
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- HealthPartners Frauenshuh Cancer Center CRC West, Saint Louis Park
- HealthPartners Cancer Center at Regions Hospital CRC East, Saint Paul
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- University Of Minnesota Medical Center, Minneapolis
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07164443Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- University of Minnesota Medical Center, Minneapolis
- Mayo Clinic, Rochester
RecruitingPhase 1
Ages 18 to 100 · Men · Updated Aug 13, 2026 · NCT0551944964Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
- Mayo Clinic, Rochester
RecruitingPhase 1/2
Ages 18 and older · Men · Updated May 6, 2026 · NCT04868604From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.